Healthcare
Live Price
Offline$188.63
+1.26% today
1Y Change
-24.27%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ResMed Inc. (RMD) is a Healthcare stock with a market cap of $29.87B and listed on NYSE. The stock last traded around $188.63 and down 24.3% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +9.8%, EPS growth of +37.6%, a dividend yield of 1.1%. What stands out right now is revenue +9.8%, EPS +37.6%, free cash flow +29.2% with operating margin 34.3% and ROIC 19.6%. The dividend is present but secondary, with a yield around 1.1%. Valuation sits in the middle of the pack at P/E 19.8 and price/sales 5.4. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines RMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RMD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RMD Max Drawdown
-37.76%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RMD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.2B
-10.7% YoY
FY Net Income
$474.5M
-39.1% YoY
Free Cash Flow
$619.9M
+217.7% YoY
Revenue Growth
+9.8%
EPS Growth
+37.6%
Gross Margin
61.7%
Net Margin
27.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5.1B | 4.7B | 4.2B | 3.6B | 3.2B |
| Gross Profit | 3.1B | 2.7B | 2.4B | 2.0B | 1.8B |
| Operating Income | 1.7B | 1.3B | 1.1B | 1.0B | 904M |
| EBITDA | 1.9B | 1.5B | 1.4B | 1.2B | 1.1B |
| Net Income | 1.4B | 1.0B | 898M | 779M | 475M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.2B | 238M | 228M | 274M | 295M |
| Total Assets | 8.2B | 6.9B | 6.8B | 5.1B | 4.7B |
| Total Liabilities | 2.2B | 2.0B | 2.6B | 1.7B | 1.8B |
| Shareholder Equity | 6.0B | 4.9B | 4.1B | 3.4B | 2.9B |
| Total Debt | 852M | 874M | 1.6B | 918M | 794M |
| Net Debt | -358M | 636M | 1.4B | 644M | 498M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
737M
+109.8% YoY
Capital Expenditures
117M
+25.1% YoY
Free Cash Flow
620M
+217.7% YoY
Key ratios
Gross Margin
61.7%
Operating Margin
34.3%
Net Margin
27.4%
ROE
24.4%
Debt / Equity
0.13x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.